Zegerid Switch Progress Generates Bottom Line Help For Santarus
This article was originally published in The Tan Sheet
Executive Summary
Santarus' OTC licensing of its Zegerid Rx heartburn remedy to Schering-Plough has yet to pay dividends for S-P, but the deal is already helping Santarus reduce its net loss